Zomedica Corp

Zomedica Corp (ZOM)

$0.1963

[object Object]

(-1.36%)

Market is closed - opens 7 PM, 05 Jun 2023

Insights on Zomedica Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 14.15M → 5.48M (in $), with an average decrease of 61.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -12.02M → -6.38M (in $), with an average increase of 88.3% per quarter

  • Vs ZTS

    In the last 1 year, Zoetis Inc - Class A has given 1.7% return, outperforming this stock by 23.1%

  • Vs ZTS

    In the last 3 years, Zoetis Inc - Class A has given 22.3% return, outperforming this stock by 6.8%

Performance

  • $0.19
    $0.20
    $0.20
    downward going graph

    3.15%

    Downside

    Day's Volatility :3.44%

    Upside

    0.3%

    downward going graph
  • $0.15
    $0.41
    $0.20
    downward going graph

    25.0%

    Downside

    52 Weeks Volatility :63.41%

    Upside

    51.22%

    downward going graph

Returns

PeriodZomedica CorpSector (Health Care)Index (Russel 2000)
3 Months
-21.57%
0.9%
-8.3%
6 Months
-3.3%
-6.8%
-6.5%
1 Year
-23.29%
0.4%
-6.1%
3 Years
15.54%
28.3%
21.8%

Highlights

Market Capitalization
195.0M
Book Value
$0.27
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.02
Wall Street Target Price
0.44
Profit Margin
-94.2%
Operating Margin TTM
-121.59%
Return On Assets TTM
-5.63%
Return On Equity TTM
-7.32%
Revenue TTM
20.7M
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
46.1%
Gross Profit TTM
13.7M
EBITDA
-20.5M
Diluted Eps TTM
-0.02
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.01
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Zomedica Corp(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 124.15%

Current $0.20
Target $0.44

Technicals Summary

Sell

Neutral

Buy

Zomedica Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zomedica Corp
Zomedica Corp
-2.24%
-3.3%
-23.29%
15.54%
-89.98%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-3.67%
-25.55%
-1.95%
-23.14%
-8.16%
Zoetis Inc.
Zoetis Inc.
-3.69%
10.65%
0.51%
22.32%
101.29%
Viatris Inc.
Viatris Inc.
3.44%
-14.56%
-20.73%
-42.9%
-42.9%
Catalent, Inc.
Catalent, Inc.
-23.38%
-25.7%
-66.09%
-50.96%
-4.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zomedica Corp
Zomedica Corp
NA
NA
NA
-0.01
-0.07
-0.06
0.0
0.27
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
144.75
144.75
1.87
2.1
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
36.8
36.8
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.88
5.88
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
16.06
16.06
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zomedica Corp
Zomedica Corp
Buy
$195.0M
-89.98%
NA
-94.2%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$8.9B
-8.16%
144.75
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$75.3B
101.29%
36.8
25.59%
Viatris Inc.
Viatris Inc.
Hold
$11.1B
-42.9%
5.88
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.7B
-4.0%
16.06
8.62%

Corporate Announcements

  • Zomedica Corp Earnings

    Zomedica Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care.

Organization
Zomedica Corp
Employees
85
CEO
Mr. Larry C. Heaton II
Industry
Health Technology

FAQs